Affiliation:
1. Laboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasília, Brasilia 70910-900, DF, Brazil
2. School of Heath Sciences, Campus Universitário Darcy Ribeiro, s/n, Brasilia 70910-900, DF, Brazil
Abstract
Alopecia areata is managed with oral corticosteroids, which has known side effects for patients. Given that a topical application of formulations containing a corticoid and a substance controlling hair loss progression could reduce or eliminate such adverse effects and increase the patient’s adherence to the treatment, this study prepares polymeric and lipidic nanoparticles (PNPs and NLCs) to co-entrap minoxidil and betamethasone and compares the follicular drug delivery provided by topical application of these nanoparticles. The prepared PNPs loaded 99.1 ± 13.0% minoxidil and 70.2 ± 12.8% betamethasone, while the NLCs entrapped 99.4 ± 0.1 minoxidil and 80.7 ± 0.1% betamethasone. PNPs and NLCs presented diameters in the same range, varying from 414 ± 10 nm to 567 ± 30 nm. The thermal analysis revealed that the production conditions favor the solubilization of the drugs in the nanoparticles, preserving their stability. In in vitro permeation studies with porcine skin, PNPs provided a 2.6-fold increase in minoxidil penetration into the follicular casts compared to the control and no remarkable difference in terms of betamethasone; in contrast, NLCs provided a significant (specifically, a tenfold) increase in minoxidil penetration into the hair follicles compared to the control, and they delivered higher concentrations of betamethasone in hair follicles than both PNPs and the control. Neither PNPs nor NLCs promoted transdermal permeation of the drugs to the receptor solution, which should favor a topical therapy. Furthermore, both nanoparticles targeted approximately 50% of minoxidil delivery to the follicular casts and NLCs targeted 74% of betamethasone delivery to the hair follicles. In conclusion, PNPs and NLCs are promising drug delivery systems for enhancing follicular targeting of drugs, but NLCs showed superior performance for lipophilic drugs.
Funder
Brazilian agency Fundação de Apoio à Pesquisa do Distrito Federal
University of Brasilia
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference44 articles.
1. Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis;Strazzulla;J. Am. Acad. Dermatol.,2018
2. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis;Lee;J. Am. Acad. Dermatol.,2020
3. Treatment of alopecia areata: An Australian expert consensus statement;Cranwell;Australas. J. Dermatol.,2019
4. Minoxidil for patchy alopecia areata: Systematic review and meta-analysis;Freire;J. Eur. Acad. Dermatol. Venereol.,2019
5. Mesalazine in the Treatment of Extensive Alopecia Areata: A New Therapeutic Option?;Kiszewski;Int. J. Trichol.,2018
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献